Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization

  • Authors:
    • Anja Lautem
    • Frank Simon
    • Maria Hoppe‑Lotichius
    • Jens Mittler
    • Johanna  Vollmar
    • Arno Schad
    • Christoph Düber
    • Peter Robert Galle
    • Gerd Otto
    • Tim Zimmermann
    • Hauke Lang
  • View Affiliations

  • Published online on: February 1, 2019     https://doi.org/10.3892/or.2019.6995
  • Pages: 2299-2310
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatocellular carcinoma (HCC) is one of the most common human malignancies, the incidence of which is growing worldwide. The prognosis of HCC is very poor and it is often accompanied by a high rate of recurrence. Conventional chemotherapeutic approaches are largely inefficient. In order to develop novel effective methods for the early detection and prognosis of HCC, novel markers and therapeutic targets are urgently required. The present study focused on the effects of the expression of the tumor suppressor gene insulin‑like growth factor‑2 receptor (IGF2R) on patient survival and tumor recurrence in patients with HCC; this study paid specific attention to the influence of transarterial chemoembolization (TACE) prior to surgery. The mRNA expression levels of IGF2R were measured in primary human HCC and corresponding non‑neoplastic tumor‑surrounding tissue (TST) by reverse transcription‑polymerase chain reaction (RT‑PCR) (n=92). Subsequently, the associations between IGF2R expression and clinicopathological parameters, outcomes of HCC and TACE pretreatment prior to surgery were determined. Furthermore, the effects of the IGF2R gene polymorphisms rs629849 and rs642588 on susceptibility and on clinicopathological features of HCC were investigated. RT‑PCR demonstrated that the mRNA expression levels of IGF2R were downregulated in HCC compared with in TST samples (P=0.004), which was associated with a worse recurrence‑free survival of patients with HCC (P=0.002) and a lower occurrence of cirrhosis (P=0.05). TACE‑pretreated patients with HCC (n=26) exhibited significantly higher IGF2R mRNA expression in tumor tissues (P=0.019). In addition, significantly more patients with HCC in the TACE‑pretreated group exhibited upregulated IGF2R mRNA expression compared with in the non‑treated patients (P=0.032). The IGF2R SNPs rs629849 and rs642588 were not significantly associated with HCC risk, whereas a homozygous IGF2R rs629849 GG genotype was associated with a significantly elevated risk of non‑viral liver cirrhosis (P=0.05). In conclusion, these data suggested an important role for IGF2R expression in HCC, particularly with regards to TACE treatment prior to surgery.

References

1 

El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Breuhahn K: Molecular mechanisms of progression in human hepatocarcinogenesis. Pathologe (31. (Suppl):2:S170–S176. 2010.(In German). View Article : Google Scholar

5 

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI

6 

Dhanasekaran R, Limaye A and Cabrera R: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 4:19–37. 2012.PubMed/NCBI

7 

Nguyen VT, Law MG and Dore GJ: Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar : PubMed/NCBI

8 

Schwartz M: Liver transplantation for hepatocellular carcinoma. Gastroenterology. 127:S268–S276. 2004. View Article : Google Scholar : PubMed/NCBI

9 

Lencioni R: Chemoembolization in patients with hepatocellular carcinoma. Liver Cancer. 1:41–50. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Boudjema K, Calmus Y, et al: Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl. 11:767–775. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R Jr, Kerlan R, Venook A, Ascher NL, Emond JC and Roberts JP: The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 5:795–804. 2005. View Article : Google Scholar : PubMed/NCBI

12 

Wang YX, De Baere T, Idee JM and Ballet S: Transcatheter embolization therapy in liver cancer: An update of clinical evidences. Chin J Cancer Res. 27:96–121. 2015.PubMed/NCBI

13 

Bouchard-Fortier A, Lapointe R, Perreault P, Bouchard L and Pomier-Layrargues G: Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: A retrospective study. Int J Hepatol. 2011:9745142011. View Article : Google Scholar : PubMed/NCBI

14 

Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A and Silva MA: Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 98:1201–1208. 2011. View Article : Google Scholar : PubMed/NCBI

15 

Millonig G, Graziadei IW, Freund MC, Jaschke W, Stadlmann S, Ladurner R, Margreiter R and Vogel W: Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 13:272–279. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Zhang Z, Liu Q, He J, Yang J, Yang G and Wu M: The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer. 89:2606–2612. 2000. View Article : Google Scholar : PubMed/NCBI

17 

Otto G, Herber S, Heise M, Lohse AW, Mönch C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A and Pitton M: Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 12:1260–1267. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Kasprzak A, Kwasniewski W, Adamek A and Gozdzicka- Jozefiak A: Insulin-like growth factor (IGF) axis in cancerogenesis. Mutat Res Rev Mutat Res. 772:78–104. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Wu J and Zhu AX: Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 4:302011. View Article : Google Scholar : PubMed/NCBI

20 

Elmashad N, Ibrahim WS, Mayah WW, Farouk M, Ali LA, Taha A and Elmashad W: Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma. Asian Pac J Cancer Prev. 16:613–619. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Espelund U, Gronbaek H, Villadsen GE, Simonsen K, Vestergaard PF, Jørgensen JO, Flyvbjerg A, Vilstrup H and Frystyk J: The circulating IGF system in hepatocellular carcinoma: The impact of liver status and treatment. Growth Horm IGF Res. 25:174–181. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Mazziotti G, Sorvillo F, Morisco F, Carbone A, Rotondi M, Stornaiuolo G, Precone DF, Cioffi M, Gaeta GB, Caporaso N and Carella C: Serum insulin-like growth factor I evaluation as a useful tool for predicting the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A prospective study. Cancer. 95:2539–2545. 2002. View Article : Google Scholar : PubMed/NCBI

23 

Rehem RN and El-Shikh WM: Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology. 58:949–954. 2011.PubMed/NCBI

24 

Su WW, Lee KT, Yeh YT, Soon MS, Wang CL, Yu ML and Wang SN: Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: One cross-sectional correlation study. J Clin Lab Anal. 24:195–200. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Chun YS, Huang M, Rink L and Von Mehren M: Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: A retrospective study. World J Surg Oncol. 12:2312014. View Article : Google Scholar : PubMed/NCBI

26 

Dong Z, Yao M, Wang L, Yan X, Gu X, Shi Y, Yao N, Qiu L, Wu W and Yao D: Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells. Tumour Biol. 34:3397–3405. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Souza RF, Wang S, Thakar M, Smolinski KN, Yin J, Zou TT, Kong D, Abraham JM, Toretsky JA and Meltzer SJ: Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells. Oncogene. 18:4063–4068. 1999. View Article : Google Scholar : PubMed/NCBI

28 

Chen Z, Ge Y, Landman N and Kang JX: Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells. BMC Cancer. 2:182002. View Article : Google Scholar : PubMed/NCBI

29 

Lu ZL, Luo DZ and Wen JM: Expression and significance of tumor-related genes in HCC. World J Gastroenterol. 11:3850–3854. 2005. View Article : Google Scholar : PubMed/NCBI

30 

Causin C, Waheed A, Braulke T, Junghans U, Maly P, Humbel RE and von Figura K: Mannose 6-phosphate/insulin-like growth factor II-binding proteins in human serum and urine. Their relation to the mannose 6-phosphate/insulin-like growth factor II receptor. Biochem J. 252:795–799. 1988. View Article : Google Scholar : PubMed/NCBI

31 

Jirtle RL, Hankins GR, Reisenbichler H and Boyer IJ: Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital. Carcinogenesis. 15:1473–1478. 1994. View Article : Google Scholar : PubMed/NCBI

32 

Kornfeld S: Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu Rev Biochem. 61:307–330. 1992. View Article : Google Scholar : PubMed/NCBI

33 

Denley A, Cosgrove LJ, Booker GW, Wallace JC and Forbes BE: Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 16:421–439. 2005. View Article : Google Scholar : PubMed/NCBI

34 

Enguita-German M and Fortes P: Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol. 6:716–737. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Chu CH, Huang CY, Lu MC, Lin JA, Tsai FJ, Tsai CH, Chu CY, Kuo WH, Chen LM and Chen LY: Enhancement of AG1024-induced H9c2 cardiomyoblast cell apoptosis via the interaction of IGF2R with Galpha proteins and its downstream PKA and PLC-beta modulators by IGF-II. Chin J Physiol. 52:31–37. 2009. View Article : Google Scholar : PubMed/NCBI

36 

Chu CH, Tzang BS, Chen LM, Kuo CH, Cheng YC, Chen LY, Tsai FJ, Tsai CH, Kuo WW and Huang CY: IGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Galphaq interaction and protein kinase C-alpha/CaMKII activation in H9c2 cardiomyoblast cells. J Endocrinol. 197:381–390. 2008. View Article : Google Scholar : PubMed/NCBI

37 

Wang KC, Brooks DA, Botting KJ and Morrison JL: IGF-2R-mediated signaling results in hypertrophy of cultured cardiomyocytes from fetal sheep. Biol Reprod. 86:1832012. View Article : Google Scholar : PubMed/NCBI

38 

Dennis PA and Rifkin DB: Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. Proc Natl Acad Sci USA. 88:580–584. 1991. View Article : Google Scholar : PubMed/NCBI

39 

Ghosh P, Dahms NM and Kornfeld S: Mannose 6-phosphate receptors: New twists in the tale. Nat Rev Mol Cell Biol. 4:202–212. 2003. View Article : Google Scholar : PubMed/NCBI

40 

Nahon P and Zucman-Rossi J: Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol. 57:663–674. 2012. View Article : Google Scholar : PubMed/NCBI

41 

Weng CJ, Hsieh YH, Tsai CM, Chu YH, Ueng KC, Liu YF, Yeh YH, Su SC, Chen YC, Chen MK, et al: Relationship of insulin-like growth factors system gene polymorphisms with the susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 17:1808–1815. 2010. View Article : Google Scholar : PubMed/NCBI

42 

Rezgui D, Williams C, Savage SA, Prince SN, Zaccheo OJ, Jones EY, Crump MP and Hassan AB: Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth. J Mol Endocrinol. 42:341–356. 2009. View Article : Google Scholar : PubMed/NCBI

43 

DaCosta SA, Schumaker LM and Ellis MJ: Mannose 6-phosphate/insulin-like growth factor 2 receptor, a bona fide tumor suppressor gene or just a promising candidate? J Mammary Gland Biol Neoplasia. 5:85–94. 2000. View Article : Google Scholar : PubMed/NCBI

44 

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI

45 

Geller DS, Morris J, Revskaya E, Kahn M, Zhang W, Piperdi S, Park A, Koirala P, Guzik H, Hall C, et al: Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl Med Biol. 43:812–817. 2016. View Article : Google Scholar : PubMed/NCBI

46 

Lee JS, Weiss J, Martin JL and Scott CD: Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer. 107:564–570. 2003. View Article : Google Scholar : PubMed/NCBI

47 

O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM and Scott CD: Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo. Endocrinology. 143:4287–4294. 2002. View Article : Google Scholar : PubMed/NCBI

48 

Otto G, Heise M, Moench C, Herber S, Bittinger F, Schuchmann M, Hoppe-Lotichius M and Pitton M: Transarterial chemoembolization before liver transplantation in 60 patients with hepatocellular carcinoma. Transplant Proc. 39:537–539. 2007. View Article : Google Scholar : PubMed/NCBI

49 

Shneor D, Folberg R, Pe'er J, Honigman A and Frenkel S: Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma. Cancer Gene Ther. 24:64–74. 2017. View Article : Google Scholar : PubMed/NCBI

50 

Harris AL: Hypoxia-A key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI

51 

Rashad NM, El-Shal AS, Abd Elbary EH, Abo Warda MH and Hegazy O: Impact of insulin-like growth factor 2, insulin-like growth factor receptor 2, insulin receptor substrate 2 genes polymorphisms on susceptibility and clinicopathological features of hepatocellular carcinoma. Cytokine. 68:50–58. 2014. View Article : Google Scholar : PubMed/NCBI

52 

de Bleser PJ, Jannes P, van Buul-Offers SC, Hoogerbrugge CM, van Schravendijk CF, Niki T, Rogiers V, van den Brande JL, Wisse E and Geerts A: Insulinlike growth factor-II/mannose 6-phosphate receptor is expressed on CCl4-exposed rat fat-storing cells and facilitates activation of latent transforming growth factor-beta in cocultures with sinusoidal endothelial cells. Hepatology. 21:1429–1437. 1995. View Article : Google Scholar : PubMed/NCBI

53 

Brandao DF, Ramalho LN, Ramalho FS, Zucoloto S, Martinelli Ade L and Silva Ode C: Liver cirrhosis and hepatic stellate cells. Acta Cir Bras. 1:54–57. 2006. View Article : Google Scholar

Related Articles

Journal Cover

April 2019
Volume 41 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lautem, A., Simon, F., Hoppe‑Lotichius, M., Mittler, J., Vollmar, J., Schad, A. ... Lang, H. (2019). Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization. Oncology Reports, 41, 2299-2310. https://doi.org/10.3892/or.2019.6995
MLA
Lautem, A., Simon, F., Hoppe‑Lotichius, M., Mittler, J., Vollmar, J., Schad, A., Düber, C., Galle, P. R., Otto, G., Zimmermann, T., Lang, H."Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization". Oncology Reports 41.4 (2019): 2299-2310.
Chicago
Lautem, A., Simon, F., Hoppe‑Lotichius, M., Mittler, J., Vollmar, J., Schad, A., Düber, C., Galle, P. R., Otto, G., Zimmermann, T., Lang, H."Expression and prognostic significance of insulin‑like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization". Oncology Reports 41, no. 4 (2019): 2299-2310. https://doi.org/10.3892/or.2019.6995